- Services & Solutions
- Clients & Partners
Chemical, Biological, Radiological, Nuclear and Explosives Defense
Chemical, biological, radiological, nuclear, and explosives (CBRNe) defense incidents could cause mass casualties in military and civilian areas. Attack scenarios could include poison, "dirty bombs" that use radiological elements, or bio-agent dispersals.
SRI addresses critical CBRNe defense needs for government and commercial clients. Examples include:
For the Biomedical Advanced Research and Development Authority (BARDA) SRI is developing a handheld device to triage individuals who may have been exposed to ionizing radiation after a radiological or nuclear incident.
For the Department of Homeland Security, SRI is developing immunological assays for the detection of ricin, abrin, and botulinum toxins.
For the National Institute of Neurological Disorders and Stroke Counter-Measures against Chemical Threats (CounterAct) program, SRI is providing preclinical development of therapeutics against chemical warfare agents.
SRI is developing therapeutics and vaccines against a wide variety of biodefense pathogens for the Division of Microbiology and Infectious Disease of the National Institute of Allergy and Infectious Disease (NIAID). SRI is also developing an oral drug for chelation of radioisotopes for NIAID.
Together with GexCon US, SRI is designing and conducting experiments to improve and validate tools used to minimize the risk of explosions or fires on offshore platforms.
SRI is developing a method to enable rapid, large-scale response to a bioterrorism threat or an infectious disease epidemic.
A new oral version of a known chelating agent can defend against mass radiation exposure in a terrorist attack.
In a nuclear or radiological incident, first responders must quickly measure the radiation exposure of a large number of individuals, since treatment options are radiation dose-dependent and time-sensitive. SRI is developing a biodosimeter to meet this critical challenge.